Etimicin
Etimicin is a fourth-generation semisynthetic aminoglycoside antibiotic. Etimicin exhibits broad spectrum of activity against gram-positive, gram-negative, and aminoglycoside-resistant bacterial strains, with lower ototoxicity and nephrotoxicity. Etimicin exerts rapid, concentration-dependent bactericidal activity against bacteria. Etimicin can be used for the research of bacterial infections.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 59711-96-5
- Fòrmula: C21H43N5O7
- Peso molecular:477.60
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Ver todos los productos específicos de isoformas Antibiotic
More
Actividad biológica
Descripciòn
IC50 & Target
[1]|
Aminoglycoside |
In Vitro
Etimicin (10 μg; 18 h) exhibits broad spectrum of activity against both gram positive and gram negative bacterial, with the highest activity against Klebsiella pneumoniae with a zone of inhibition of 31.29 mm[1].
Etimicin (18-24 h) inhibits growth of typed bacterial strains with MIC values ranging from 0.125 to 0.5 mg/L, with the lowest potency against Acinetobacter baumanii MTCC-1425 (MIC = 0.5 mg/L) and highest potency against Proteus mirabilis MTCC-425, Salmonella typhi MTCC-535, and Escherichia coli MTCC-739 (MIC = 0.125 mg/L)[1].
Etimicin (18-24 h) exerts bactericidal effects against typed bacterial strains with MBC values ranging from 0.25 to 2 mg/L, with the highest bactericidal potency against Escherichia coli MTCC-739 (MBC = 0.25 mg/L) and lowest potency against Acinetobacter baumanii MTCC-1425, Serratia grimesii MTCC-1887, Klebsiella pneumoniae MTCC-109, Enterobacter cloacae MTCC-509, and Staphylococcus aureus MTCC-737 (MBC = 2 mg/L)[1].
Etimicin (18-24 h) inhibits growth of 279 aminoglycoside-susceptible clinical bacterial isolates with MIC50 values ranging from 0.25 to 1 mg/L and MIC90 values ranging from 1 to 4 mg/L, with the highest potency against Escherichia coli isolates (MIC50 = 0.25 mg/L, MIC90 = 1 mg/L)[1].
Etimicin (18-24 h) inhibits growth of 128 aminoglycoside-resistant clinical bacterial isolates with MIC50 values ranging from 2 to 4 mg/L and MIC90 values ranging from 4 to 8 mg/L, with the highest potency against Escherichia coli, Klebsiella pneumoniae, and Staphylococcus species isolates (MIC50 = 2 mg/L, MIC90 = 4 mg/L)[1].
Etimicin (0.125-0.25 mg/L; 2-12 h) at its MIC concentration exhibits rapid, sustained bactericidal activity against Escherichia coli MTCC-739, Klebsiella pneumoniae MTCC-109, Staphylococcus aureus MTCC-737, and Pseudomonas aeruginosa MTCC-1688, maintaining a 2-log reduction in viable cell count for 12 h without bacterial regrowth[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Escherichia coli MTCC-739, Klebsiella pneumoniae MTCC-109, Staphylococcus aureus MTCC-737, and Pseudomonas aeruginosa MTCC-1688
-
Concentration:0.125, 0.25 mg/L
-
Incubation Time:2, 4, 6, 8, 12 h
-
Result:Exhibited rapid, sustained bactericidal activity, maintaining up to 12 h.
Chemical Information
-
No. CAS 59711-96-5
-
Peso molecular 477.60
-
Fòrmula C21H43N5O7
-
SMILES
CCN[C@H](C[C@@H]([C@H]([C@@H]1O)O[C@H]2O[C@@H](CC[C@H]2N)CN)N)[C@@H]1O[C@@H]3[C@@H]([C@H]([C@@](O)(CO3)C)NC)O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocolo
-
Nephrotoxicity Study
This protocol assesses nephrotoxicity by combining functional kidney injury readouts, urinary/tissue injury biomarkers, and renal histopathology. Serum creatinine and BUN reflect impaired kidney function, while KIM-1, NGAL, clusterin, osteopontin, IL-18, cystatin C, nephrin, Oat5, urinary protein, glucose, and alkaline phosphatase have been used to detect tubular injury in cisplatin-, gentamicin-, and acetaminophen-induced nephrotoxicity models.
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
-
Bacterial live/dead nucleic-acid viability staining
The LIVE/DEAD bacterial viability staining method is based on differential permeability of nucleic-acid-binding fluorescent dyes, most commonly SYTO 9 and propidium iodide (PI), which enables discrimination of bacterial populations with intact versus compromised cytoplasmic membranes. SYTO 9 penetrates both intact and damaged bacterial membranes and binds nucleic acids to produce green fluorescence, whereas propidium iodide penetrates only cells with compromised membranes and fluoresces red while also reducing SYTO 9 signal through competitive binding and fluorescence interactions. The resulting fluorescence pattern is interpreted as a proxy for membrane integrity, which is widely used as an indicator of bacterial viability in microscopy, flow cytometry, and spectroscopic platforms. However, mechanistic studies show that SYTO 9 and PI interactions involve displacement and fluorescence resonance energy transfer effects, which can influence signal interpretation depending on dye ratios a
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Etimicin
- 59711-96-5
- Antibiotic
- Bacterial
- Salmonella typhi MTCC-535
- bacterial infections
- Proteus mirabilis MTCC-425
- Escherichia coli MTCC-739
- Enterobacter cloacae MTCC-509
- Serratia grimesii MTCC-1887
- Pseudomonas aeruginosa MTCC-1688
- Staphylococcus aureus MTCC-737
- Acinetobacter baumanii MTCC-1425
- Klebsiella pneumoniae MTCC-109
- Inhibitor
- inhibitor
- inhibit